Teriflunomide 14 Teva 14 mg FC tablets
PDF Leaflet Revision Date: 07 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsing forms of multiple sclerosis.
Dosage (summary)
14 mg orally once daily.
Special Populations
- Elderly population
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP inducers (e.g., rifampicin)
- Warfarin
- CYP2C8 substrates
Contraindications
- Severe hepatic impairment
- Pregnancy
- Breastfeeding
- Severe immunodeficiency
Common side effects
- Headache
- Diarrhoea
- Increased ALT
- Nausea
- Alopecia
Counselling Points
- Use reliable contraception during treatment.
- Monitor liver enzymes regularly.
- Report any signs of infection.
Serious warnings
- Hepatotoxicity
- Risk of teratogenicity
- Serious infections
Important Disclaimer
The Teriflunomide 14 Teva 14 mg FC tablets professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
